InvestSMART

Telix Pharmaceuticals Limited (ASX:TLX)

ALERT: Price-sensitive ASX Announcement for TLX
Current share price for TLX : $14.470 3.19 (28.28%)+
Announcement
Release
20 Jan 2026 8:25AM
Price at Release
$11.280
Full Release
download
Summary
Telix Pharmaceuticals Limited announced that the Chinese National Medical Products Administration (NMPA) has accepted the New Drug Application for their prostate cancer imaging agent, TLX591-Px (Illuccix®). In collaboration with Grand Pharma, this submission marks Telix's first product application in China, a strategic market for the company. The Illuccix China Pivotal Phase 3 Registration study demonstrated a 94.8% positive predictive value for tumor detection, impacting clinical decision-making significantly. Illuccix has already been approved in several countries, reflecting its global clinical utility.
Key Points
  • The Chinese National Medical Products Administration (NMPA) has accepted the New Drug Application for TLX591-Px (Illuccix®).
  • Telix Pharmaceuticals Limited has partnered with Grand Pharma for this submission in China.
  • Illuccix is Telix’s lead prostate cancer imaging agent.
  • The Illuccix China study achieved a 94.8% positive predictive value for tumor detection.
  • The product has already received approvals in multiple countries including the US, Australia, and several European nations.
  • Telix aims to expand geographically, with China being a critical market for growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.